Cargando…
CDX2 hox gene product in a rat model of esophageal cancer
BACKGROUND: Barrett's mucosa is the precursor of esophageal adenocarcinoma. The molecular mechanisms behind Barrett's carcinogenesis are largely unknown. Experimental models of longstanding esophageal reflux of duodenal-gastric contents may provide important information on the biological s...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3225830/ https://www.ncbi.nlm.nih.gov/pubmed/19664209 http://dx.doi.org/10.1186/1756-9966-28-108 |
_version_ | 1782217532895133696 |
---|---|
author | Ingravallo, Giuseppe Dall'Olmo, Luigi Segat, Daniela Fassan, Matteo Mescoli, Claudia Dazzo, Emanuela Castoro, Carlo Polimeno, Lorenzo Rizzetto, Christian Baroni, Maurizio David Zaninotto, Giovanni Ancona, Ermanno Rugge, Massimo |
author_facet | Ingravallo, Giuseppe Dall'Olmo, Luigi Segat, Daniela Fassan, Matteo Mescoli, Claudia Dazzo, Emanuela Castoro, Carlo Polimeno, Lorenzo Rizzetto, Christian Baroni, Maurizio David Zaninotto, Giovanni Ancona, Ermanno Rugge, Massimo |
author_sort | Ingravallo, Giuseppe |
collection | PubMed |
description | BACKGROUND: Barrett's mucosa is the precursor of esophageal adenocarcinoma. The molecular mechanisms behind Barrett's carcinogenesis are largely unknown. Experimental models of longstanding esophageal reflux of duodenal-gastric contents may provide important information on the biological sequence of the Barrett's oncogenesis. METHODS: The expression of CDX2 hox-gene product was assessed in a rat model of Barrett's carcinogenesis. Seventy-four rats underwent esophago-jejunostomy with gastric preservation. Excluding perisurgical deaths, the animals were sacrificed at various times after the surgical treatment (Group A: <10 weeks; Group B: 10–30 weeks; Group C: >30 weeks). RESULTS: No Cdx2 expression was detected in either squamous epithelia of the proximal esophagus or squamous cell carcinomas. De novo Cdx2 expression was consistently documented in the proliferative zone of the squamous epithelium close to reflux ulcers (Group A: 68%; Group B: 64%; Group C: 80%), multilayered epithelium and intestinal metaplasia (Group A: 9%; Group B: 41%; Group C: 60%), and esophageal adenocarcinomas (Group B: 36%; Group C: 35%). A trend for increasing overall Cdx2 expression was documented during the course of the experiment (p = 0.001). CONCLUSION: De novo expression of Cdx2 is an early event in the spectrum of the lesions induced by experimental gastro-esophageal reflux and should be considered as a key step in the morphogenesis of esophageal adenocarcinoma. |
format | Online Article Text |
id | pubmed-3225830 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-32258302011-11-30 CDX2 hox gene product in a rat model of esophageal cancer Ingravallo, Giuseppe Dall'Olmo, Luigi Segat, Daniela Fassan, Matteo Mescoli, Claudia Dazzo, Emanuela Castoro, Carlo Polimeno, Lorenzo Rizzetto, Christian Baroni, Maurizio David Zaninotto, Giovanni Ancona, Ermanno Rugge, Massimo J Exp Clin Cancer Res Research BACKGROUND: Barrett's mucosa is the precursor of esophageal adenocarcinoma. The molecular mechanisms behind Barrett's carcinogenesis are largely unknown. Experimental models of longstanding esophageal reflux of duodenal-gastric contents may provide important information on the biological sequence of the Barrett's oncogenesis. METHODS: The expression of CDX2 hox-gene product was assessed in a rat model of Barrett's carcinogenesis. Seventy-four rats underwent esophago-jejunostomy with gastric preservation. Excluding perisurgical deaths, the animals were sacrificed at various times after the surgical treatment (Group A: <10 weeks; Group B: 10–30 weeks; Group C: >30 weeks). RESULTS: No Cdx2 expression was detected in either squamous epithelia of the proximal esophagus or squamous cell carcinomas. De novo Cdx2 expression was consistently documented in the proliferative zone of the squamous epithelium close to reflux ulcers (Group A: 68%; Group B: 64%; Group C: 80%), multilayered epithelium and intestinal metaplasia (Group A: 9%; Group B: 41%; Group C: 60%), and esophageal adenocarcinomas (Group B: 36%; Group C: 35%). A trend for increasing overall Cdx2 expression was documented during the course of the experiment (p = 0.001). CONCLUSION: De novo expression of Cdx2 is an early event in the spectrum of the lesions induced by experimental gastro-esophageal reflux and should be considered as a key step in the morphogenesis of esophageal adenocarcinoma. BioMed Central 2009-08-07 /pmc/articles/PMC3225830/ /pubmed/19664209 http://dx.doi.org/10.1186/1756-9966-28-108 Text en Copyright ©2009 Ingravallo et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Ingravallo, Giuseppe Dall'Olmo, Luigi Segat, Daniela Fassan, Matteo Mescoli, Claudia Dazzo, Emanuela Castoro, Carlo Polimeno, Lorenzo Rizzetto, Christian Baroni, Maurizio David Zaninotto, Giovanni Ancona, Ermanno Rugge, Massimo CDX2 hox gene product in a rat model of esophageal cancer |
title | CDX2 hox gene product in a rat model of esophageal cancer |
title_full | CDX2 hox gene product in a rat model of esophageal cancer |
title_fullStr | CDX2 hox gene product in a rat model of esophageal cancer |
title_full_unstemmed | CDX2 hox gene product in a rat model of esophageal cancer |
title_short | CDX2 hox gene product in a rat model of esophageal cancer |
title_sort | cdx2 hox gene product in a rat model of esophageal cancer |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3225830/ https://www.ncbi.nlm.nih.gov/pubmed/19664209 http://dx.doi.org/10.1186/1756-9966-28-108 |
work_keys_str_mv | AT ingravallogiuseppe cdx2hoxgeneproductinaratmodelofesophagealcancer AT dallolmoluigi cdx2hoxgeneproductinaratmodelofesophagealcancer AT segatdaniela cdx2hoxgeneproductinaratmodelofesophagealcancer AT fassanmatteo cdx2hoxgeneproductinaratmodelofesophagealcancer AT mescoliclaudia cdx2hoxgeneproductinaratmodelofesophagealcancer AT dazzoemanuela cdx2hoxgeneproductinaratmodelofesophagealcancer AT castorocarlo cdx2hoxgeneproductinaratmodelofesophagealcancer AT polimenolorenzo cdx2hoxgeneproductinaratmodelofesophagealcancer AT rizzettochristian cdx2hoxgeneproductinaratmodelofesophagealcancer AT baronimauriziodavid cdx2hoxgeneproductinaratmodelofesophagealcancer AT zaninottogiovanni cdx2hoxgeneproductinaratmodelofesophagealcancer AT anconaermanno cdx2hoxgeneproductinaratmodelofesophagealcancer AT ruggemassimo cdx2hoxgeneproductinaratmodelofesophagealcancer |